Fapon Biotech
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Fapon Biotech Inc., founded in 2001, is a global life sciences company supplying the in-vitro diagnostics (IVD) industry: high-performance reagent raw materials (antigens, antibodies, enzymes), reagent solutions, and innovative open instrument platforms for diagnostic companies worldwide. Its products are present in 68 countries and regions, serving more than 2,500 business partners, and its sister company Fapon Biopharma develops therapeutic antibodies and fusion proteins (lead asset FP008 in Phase 1). The company exhibited at BIO 2025 and Medlab Middle East 2024 and maintains an active global R&D, manufacturing, sales, and service network.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Fapon Biotech was founded in 2001 to provide IVD reagent raw materials — antigens, antibodies, enzymes — to global diagnostic companies.
- Middle East expansion
Fapon partnered with the China Innovation Center at Dubai Chambers to introduce its diagnostics and therapeutics technologies to the Middle East healthcare market.
- Active operations
Fapon exhibited at Medlab Middle East 2024, advancing IVD technologies and local healthcare partnerships; no verifiable 2024 failure event was found.
- BIO 2025
Fapon Biopharma showcased its differentiated pipeline, including Phase 1 immunocytokine FP008, at the BIO International Convention 2025 in Boston.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.